Long-term results of stem cell transplantation for MS

@article{Fassas2011LongtermRO,
  title={Long-term results of stem cell transplantation for MS},
  author={Athanasios Fassas and V K Kimiskidis and Ioanna Sakellari and K. Kapinas and A. Anagnostopoulos and Vaia Tsimourtou and Kyriaki Sotirakoglou and Aristides D. Kazis},
  journal={Neurology},
  year={2011},
  volume={76},
  pages={1066 - 1070}
}
Objective: To report long-term results of a phase I/II study conducted in a single center in order to investigate the effect of hemopoietic stem cell transplantation (HSCT) in the treatment of multiple sclerosis (MS). Methods: Clinical and MRI outcomes of 35 patients with aggressive MS treated with HSCT are reported after a median follow-up period of 11 (range 2–15) years. Results: Disease progression-free survival (PFS) at 15 years is 44% for patients with active CNS disease and 10% for those… 

Figures from this paper

Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway
TLDR
HSCT in MS is an effective and relatively safe treatment option, with few serious complications and no mortality in Norway, so far, however, long-term adverse event with amenorrhea is a common problem.
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
TLDR
In this observational study of patients with MS treated with AHSCT, almost half of them remained free from neurological progression for 5 years after transplant, supporting the rationale for further randomized clinical trials of AHS CT for the treatment of MS.
Long-term follow-up more than 10 years after HSCT: a monocentric experience
TLDR
The results confirm in a long follow-up the efficacy of HSCT in reducing relapses and disability progression and the risk/benefit profile is better for intermediate intensity regimens.
Autologous hematopoietic stem cell transplantation in multiple sclerosis
TLDR
The emerging evidence on immunoablative therapy followed by autologous hematopoietic stem cell transplantation to manage severe and treatment-refractory multiple sclerosis indicates that the largest benefit/risk profile form this therapeutic approach can be obtained in patients with aggressive MS with a relapsing-remitting course and who have not yet accumulated a high level of disability.
Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives
TLDR
The risk/benefit ratio of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in the population of MS patients is very favorable, and the consistency of the long-term clinical and quality of life results are in favor of the efficacy and safety of this treatment approach in MS patients.
Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China
TLDR
AHSCT is a feasible treatment for severe MS and its long-term efficacy is favorable, and the major early toxicity resulted in fever and late toxicity caused transplantation-related mortality due to severe pneumonia and varicella-zoster virus hepatitis, respectively.
Autologous hematopoietic stem cell transplantation in multiple sclerosis
TLDR
Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS, and these results strongly support further phase III studies with primary clinical endpoints.
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience
TLDR
This study shows that AHSCT with a BEAM/ATG conditioning regimen has a sustained effect in suppressing disease progression in aggressive MS cases unresponsive to conventional therapies and can also cause a sustained clinical improvement, especially if treated subjects are still in the relapsing–remitting phase of the disease.
Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis
TLDR
This case report is a novel evidence for autologous hematopoietic stem cell transplantation (HSCT) in progressive MS, and needs to be tested in well-designed randomized trial.
Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience
TLDR
A large, randomized clinical study comparing AHSCT with the best approved therapies is still necessary to confirm the role of transplantation in MS treatment, supported by immunological data that suggest the possibility of a resetting of the immune system after A HSCT.
...
...

References

SHOWING 1-10 OF 13 REFERENCES
Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation
TLDR
This small series of patients with “malignant” relapsing–remitting MS suggests HSCT to be an effective treatment option for this relatively rare disease course, and suggests that future criteria for HSCT in MS should be close to the present ones.
Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases
TLDR
Two cases with very active, relapsing-remitting MS, who underwent AHSCT, and obtained a dramatic resolution to disease activity are reported.
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
TLDR
The treatment with intense immune ablation followed by ASCT of three patients with malignant MS whose clinical course indicated a dramatically poor prognosis succeeded in halting the rapidly worsening course of disease.
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
TLDR
HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.
Can the Expanded Disability Status Scale be assessed by telephone?
TLDR
The telepho ne questionnaire is a valid tool to assess EDSS score in cases where the patient is unable to continue visiting a study centre or in long-term follow-up of trial participants.
Multiple sclerosis.
Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study
TLDR
Autologous HSCT appears feasible in MS; it does not aggravate disability and seems to offer a clinical benefit, however, these observations need confirmation and long-term outcomes will show if benefits counterbalance toxicity and cost.
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
TLDR
These data are the first to demonstrate that long-term suppression of inflammatory activity in MS patients who received HSCT does not depend on persisting lymphopenia and is associated with profound qualitative immunological changes that demonstrate a de novo regeneration of the T cell compartment.
Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631–638
  • 1997
Aloha" to More of What YOU Want
  • 2011
...
...